However, to date, despite proven safety and tolerability at clinical trials, neither recombinant forms of TRAIL nor antibodies against TRAIL-R1/R2 showed a favorable clinical response in cancer patients, mainly due to the resistance mechanism [27]. Here, TNFSF10 is linked to cancer.